Intuitive Surgical's Q4 revenue rises 19%, EPS beats estimates

Overview

• Surgical robots maker's Q4 revenue rose 19%, driven by increased procedure volume

• Adjusted EPS beat analysts' expectations

• Adjusted net income exceeded analysts' estimates

Outlook

• Intuitive expects worldwide da Vinci procedure growth of 13% to 15% in 2026

• Company forecasts non-GAAP gross profit margin between 67% and 68% for 2026

• Intuitive anticipates non-GAAP operating expense growth of 11% to 15% in 2026

Result Drivers

• PROCEDURE GROWTH - Worldwide procedures grew 18%, with da Vinci up 17% and Ion up 44%

• SYSTEM PLACEMENTS - Da Vinci system placements increased to 532, including 303 da Vinci 5 systems

• INSTALLED BASE EXPANSION - Da Vinci installed base grew 12% and Ion by 24%

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Intuitive Surgical Inc is $612.50, about 17% above its January 21 closing price of $523.69

• The stock recently traded at 54 times the next 12-month earnings vs. a P/E of 50 three months ago

Press Release: ID:nGNX6n9xZG

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.